Bart L. Scott, MD

Clinical Director, MDS/MPN and Myeloid Malignancies
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Clinical expertise
Bone marrow transplantation, leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)
“I know your disease and the latest treatments, but only you can guide me to meet your health needs.”
— Dr. Scott
What is your personal experience with cancer?

Cancer survivor, family member of a patient, physician — I’ve been all three. When I was in high school, my mom was diagnosed with breast cancer. After watching her go through what she did and seeing the doctors work with her, I knew that I wanted to be a doctor, too. Then, in my second year of medical school, I was diagnosed with Hodgkin lymphoma. That’s when I learned firsthand about the benefits of people participating in clinical trials. Thanks to those patients, I survived a disease that once had a high mortality rate. These experiences have made me more aware of what patients and families go through when cancer barges into their lives.

What do you want patients to know about clinical trials?

There’s often a misconception that participating in a clinical trial means you won’t get the best treatment. Actually, the opposite is true. Those who decide to join a trial tend to get far superior treatment compared to those who don’t. One reason is the level of monitoring: A team of experts in your particular disease will oversee your care very closely. Another reason is that you have access to the very latest therapies available, which may be more effective than conventional methods. There are no placebos. In the end, you have to decide what’s right for you, and clinical trials aren’t without risk. But choosing to participate in one means that you have the chance to help future patients while also helping yourself.

Provider background

Specialties and clinical expertise: Hematologic malignancies

Myelodysplastic syndromes (MDS)

I am the director of hematology and hematologic malignancies at SCCA as well as a medical oncologist who specializes in treating myelodysplastic syndromes (MDS). Sometimes referred to as “preleukemia,” MDS refers to a group of disorders in which the bone marrow fails to produce enough healthy blood cells. Treatment of this disease is improving rapidly because of clinical trials. I’m currently developing three treatment protocols for MDS, which affects between 13,000 and 20,000 patients in the U.S. every year. In addition to conducting research, I’m also focused on day-to-day patient interactions. In 2016, I received the Ali Al-Johani Award, which recognizes excellence in clinical patient care.

Myeloproliferative neoplasms (MPN)

One of my subspecialties is treating myeloproliferative neoplasms (MPN), a rare group of blood cancers caused by an overproduction of white or red blood cells or platelets. I coordinate the care of patients with MPN from all over the world, and I also conduct clinical trials of new drug therapies, such as pacritinib, for these cancers. In recent years, we’ve made a lot of progress in understanding the basic biology of MPN — in particular, some of the mutations that drive it — which makes it possible to develop more targeted therapies with fewer side effects.

Diseases treated

Education, experience and certifications
Undergraduate Degree
University of Alabama, Birmingham
Medical Degree
University of South Alabama-Mobile, School of Medicine
Johns Hopkins University, School of Medicine
University of Washington, Hematology-Oncology
Board Certification
Medical Oncology, 2003, 2019, American Board of Internal Medicine


Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)
Complete title
Initial Cytoreductive Therapy for Myelodysplastic Syndrome prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)
Study ID:
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Complete title
A Pilot Study of CPX-351 (Vyxeos) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome
Study ID:
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Complete title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib


Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.


SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers